Actuate Therapeutics (ACTU) vs Dyadic International (DYAI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Dyadic International (DYAI) has outperformed Actuate Therapeutics (ACTU) over the past year, losing 60.7% versus a loss of 90.3%. Dyadic International is the larger company by market cap ($18.3 million vs $15.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACTU | DYAI |
|---|---|---|
| Share price | $0.6501 | $0.4575 |
| Market cap | $15.61M | $18.33M |
| 1-day change | -4.26% | +2.95% |
| YTD return | -88.91% | -52.72% |
| 1-year return | -90.31% | -60.67% |
| 5-year return | — | -90.84% |
| EPS (TTM) | $-0.87 | $-0.23 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.49 | $1.60 |
| 52-week low | $0.604 | $0.34 |
| Distance from 52-week high | -92.34% | -71.41% |
| Analyst consensus | none | none |
| Avg. price target upside | +1696.65% | +1102.19% |
| Average volume | 386.51K | 201.91K |
| Shares outstanding | 24.01M | 40.06M |
| Employees | 12 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- DYAI has outperformed ACTU by 29.6 percentage points over the past year.
About Actuate Therapeutics
ACTU stock →Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancers in the United States. The company's lead product candidate is elraglusib injection, a glycogen synthase kinase-3 inhibitor that is in Phase 2 trial to treat metastatic pancreatic ductal adenocarcinoma.
Health Care · Biotechnology: Pharmaceutical Preparations · 12 employees
About Dyadic International
DYAI stock →Dyadic International, Inc., together with its subsidiaries, a biotechnology platform company, develops, manufactures, and commercializes proteins and enzymes in the United States. The company offers Dapibus Protein Production Platform, a proprietary expression system designed to produce non-animal proteins and enzymes for non-pharmaceutical markets, including life sciences, food and nutrition, and bio-industrial sector; and C1 Protein Production Platform, a thermophilic fungal platform for large-scale production of proteins.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 5 employees
ACTU vs DYAI FAQ
Which is bigger, Actuate Therapeutics or Dyadic International?
Dyadic International (DYAI) is larger, with a market capitalization of $18.33M compared with $15.61M for Actuate Therapeutics (ACTU).
Which stock has performed better over the past year, ACTU or DYAI?
DYAI returned -60.67% over the past 12 months, compared with -90.31% for ACTU (price return, excluding dividends). Past performance does not predict future results.
Are Actuate Therapeutics and Dyadic International in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Pharmaceutical Preparations for Actuate Therapeutics and Biotechnology: Biological Products (No Diagnostic Substances) for Dyadic International.